The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Constantine S. Mitsiades

Corresponding Author: Constantine S. Mitsiades

Jerome Lipper Multiple Myeloma Center

Department of Medical Oncology

Dana Farber Cancer Institute

[email]@*.harvard.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Corresponding Author: Constantine S. Mitsiades, Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute. 2012
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney St. 2003 - 2011

References

  1. Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma. McMillin, D.W., Jacobs, H.M., Delmore, J.E., Buon, L., Hunter, Z.R., Monrose, V., Yu, J., Smith, P.G., Richardson, P.G., Anderson, K.C., Treon, S.P., Kung, A.L., Mitsiades, C.S. Mol. Cancer Ther. (2012) [Pubmed]
  2. Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. Mitsiades, C.S., Davies, F.E., Laubach, J.P., Joshua, D., Miguel, J.S., Anderson, K.C., Richardson, P.G. J. Clin. Oncol. (2011) [Pubmed]
  3. Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Mitsiades, C.S., Hideshima, T., Chauhan, D., McMillin, D.W., Klippel, S., Laubach, J.P., Munshi, N.C., Anderson, K.C., Richardson, P.G. Semin. Hematol. (2009) [Pubmed]
  4. Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias. Mitsiades, C.S., Rouleau, C., Echart, C., Menon, K., Teicher, B., Distaso, M., Palumbo, A., Boccadoro, M., Anderson, K.C., Iacobelli, M., Richardson, P.G. Clin. Cancer Res. (2009) [Pubmed]
  5. Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. Mitsiades, C.S., Ocio, E.M., Pandiella, A., Maiso, P., Gajate, C., Garayoa, M., Vilanova, D., Montero, J.C., Mitsiades, N., McMullan, C.J., Munshi, N.C., Hideshima, T., Chauhan, D., Aviles, P., Otero, G., Faircloth, G., Mateos, M.V., Richardson, P.G., Mollinedo, F., San-Miguel, J.F., Anderson, K.C. Cancer Res. (2008) [Pubmed]
  6. Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. Mitsiades, C.S., Mitsiades, N.S., Richardson, P.G., Munshi, N.C., Anderson, K.C. J. Cell. Biochem. (2007) [Pubmed]
  7. Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition. Mitsiades, C.S., Hayden, P., Kotoula, V., McMillin, D.W., McMullan, C., Negri, J., Delmore, J.E., Poulaki, V., Mitsiades, N. J. Clin. Endocrinol. Metab. (2007) [Pubmed]
  8. Targeting BRAFV600E in thyroid carcinoma: therapeutic implications. Mitsiades, C.S., Negri, J., McMullan, C., McMillin, D.W., Sozopoulos, E., Fanourakis, G., Voutsinas, G., Tseleni-Balafouta, S., Poulaki, V., Batt, D., Mitsiades, N. Mol. Cancer Ther. (2007) [Pubmed]
  9. The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Mitsiades, C.S., McMillin, D.W., Klippel, S., Hideshima, T., Chauhan, D., Richardson, P.G., Munshi, N.C., Anderson, K.C. Hematol. Oncol. Clin. North Am. (2007) [Pubmed]
  10. Mouse models of human myeloma. Mitsiades, C.S., Anderson, K.C., Carrasco, D.R. Hematol. Oncol. Clin. North Am. (2007) [Pubmed]
  11. Antimyeloma activity of heat shock protein-90 inhibition. Mitsiades, C.S., Mitsiades, N.S., McMullan, C.J., Poulaki, V., Kung, A.L., Davies, F.E., Morgan, G., Akiyama, M., Shringarpure, R., Munshi, N.C., Richardson, P.G., Hideshima, T., Chauhan, D., Gu, X., Bailey, C., Joseph, M., Libermann, T.A., Rosen, N.S., Anderson, K.C. Blood (2006) [Pubmed]
  12. Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation. Mitsiades, C.S., Poulaki, V., Fanourakis, G., Sozopoulos, E., McMillin, D., Wen, Z., Voutsinas, G., Tseleni-Balafouta, S., Mitsiades, N. Clin. Cancer Res. (2006) [Pubmed]
  13. Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. Mitsiades, C.S., Kotoula, V., Poulaki, V., Sozopoulos, E., Negri, J., Charalambous, E., Fanourakis, G., Voutsinas, G., Tseleni-Balafouta, S., Mitsiades, N. J. Clin. Endocrinol. Metab. (2006) [Pubmed]
  14. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. Mitsiades, C.S., McMillin, D., Kotoula, V., Poulaki, V., McMullan, C., Negri, J., Fanourakis, G., Tseleni-Balafouta, S., Ain, K.B., Mitsiades, N. J. Clin. Endocrinol. Metab. (2006) [Pubmed]
  15. Proteasome inhibition as a new therapeutic principle in hematological malignancies. Mitsiades, C.S., Mitsiades, N., Hideshima, T., Richardson, P.G., Anderson, K.C. Curr. Drug. Targets (2006) [Pubmed]
  16. CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q. Mitsiades, C.S. Haematologica (2005) [Pubmed]
  17. Proteasome inhibition as a therapeutic strategy for hematologic malignancies. Mitsiades, C.S., Mitsiades, N., Hideshima, T., Richardson, P.G., Anderson, K.C. Expert. Rev. Anticancer. Ther (2005) [Pubmed]
  18. Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling. Mitsiades, C.S., Mitsiades, N. Expert. Rev. Anticancer. Ther (2005) [Pubmed]
  19. Proteasome inhibitors as therapeutics. Mitsiades, C.S., Mitsiades, N., Hideshima, T., Richardson, P.G., Anderson, K.C. Essays Biochem. (2005) [Pubmed]
  20. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Mitsiades, C.S., Mitsiades, N.S., McMullan, C.J., Poulaki, V., Shringarpure, R., Hideshima, T., Akiyama, M., Chauhan, D., Munshi, N., Gu, X., Bailey, C., Joseph, M., Libermann, T.A., Richon, V.M., Marks, P.A., Anderson, K.C. Proc. Natl. Acad. Sci. U.S.A. (2004) [Pubmed]
  21. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Mitsiades, C.S., Mitsiades, N.S., McMullan, C.J., Poulaki, V., Shringarpure, R., Akiyama, M., Hideshima, T., Chauhan, D., Joseph, M., Libermann, T.A., García-Echeverría, C., Pearson, M.A., Hofmann, F., Anderson, K.C., Kung, A.L. Cancer. Cell (2004) [Pubmed]
  22. The Akt pathway: molecular targets for anti-cancer drug development. Mitsiades, C.S., Mitsiades, N., Koutsilieris, M. Curr. Cancer. Drug. Targets (2004) [Pubmed]
  23. Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Mitsiades, C.S., Mitsiades, N.S., Bronson, R.T., Chauhan, D., Munshi, N., Treon, S.P., Maxwell, C.A., Pilarski, L., Hideshima, T., Hoffman, R.M., Anderson, K.C. Cancer Res. (2003) [Pubmed]
 
WikiGenes - Universities